JO3156B1 - ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا - Google Patents

ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا

Info

Publication number
JO3156B1
JO3156B1 JOP/2010/0245A JOP20100245A JO3156B1 JO 3156 B1 JO3156 B1 JO 3156B1 JO P20100245 A JOP20100245 A JO P20100245A JO 3156 B1 JO3156 B1 JO 3156B1
Authority
JO
Jordan
Prior art keywords
malaria
compositions
treatment
parasitic diseases
fused imidazoles
Prior art date
Application number
JOP/2010/0245A
Other languages
English (en)
Inventor
K Chatterjee Arnab
S Nagle Advait
Wu Tao
C Tully David
L Kuhen Kelli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3156(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3156B1 publication Critical patent/JO3156B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

الإختراع يوفر نوع من المركبات، تراكيب صيدلانية تشمل مثل هذه المركبات وطرق إستعمال مثل هذه المركبات لمعالجة أو منع الملاريا.
JOP/2010/0245A 2009-07-09 2010-07-08 ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا JO3156B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22443309P 2009-07-09 2009-07-09

Publications (1)

Publication Number Publication Date
JO3156B1 true JO3156B1 (ar) 2017-09-20

Family

ID=42727573

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0245A JO3156B1 (ar) 2009-07-09 2010-07-08 ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا

Country Status (38)

Country Link
US (3) US8557801B2 (ar)
EP (2) EP2737927B1 (ar)
JP (1) JP5432376B2 (ar)
KR (1) KR101378666B1 (ar)
CN (1) CN102471341B (ar)
AR (1) AR077463A1 (ar)
AU (1) AU2010271247B2 (ar)
BR (1) BR112012000413B1 (ar)
CA (1) CA2767664C (ar)
CL (1) CL2012000042A1 (ar)
CO (1) CO6491060A2 (ar)
CR (1) CR20120008A (ar)
CU (1) CU24155B1 (ar)
DK (1) DK2451814T3 (ar)
EA (1) EA019655B1 (ar)
EC (1) ECSP12011585A (ar)
ES (2) ES2477940T3 (ar)
GT (1) GT201200004A (ar)
HK (1) HK1164304A1 (ar)
HN (1) HN2012000023A (ar)
HR (1) HRP20140641T1 (ar)
IL (1) IL217384A (ar)
JO (1) JO3156B1 (ar)
MA (1) MA33419B1 (ar)
MX (1) MX2012000389A (ar)
MY (1) MY157238A (ar)
NZ (1) NZ597275A (ar)
PE (1) PE20130399A1 (ar)
PL (1) PL2451814T3 (ar)
PT (1) PT2451814E (ar)
SG (1) SG176938A1 (ar)
SI (1) SI2451814T1 (ar)
SM (1) SMT201400096B (ar)
TN (1) TN2011000647A1 (ar)
TW (1) TWI421252B (ar)
UA (1) UA103930C2 (ar)
UY (1) UY32776A (ar)
WO (1) WO2011006143A2 (ar)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015118985A (ru) * 2012-11-14 2017-01-10 Ф. Хоффманн-Ля Рош Аг Производные имидазопиридина
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
CN105189506A (zh) * 2012-11-19 2015-12-23 诺华股份有限公司 用于治疗寄生虫疾病的化合物和组合物
ES2655030T3 (es) 2012-11-19 2018-02-16 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CN103126782B (zh) * 2013-02-26 2016-06-29 内蒙古农牧业科学院 一种寄生病的治疗方法
MX368072B (es) * 2013-12-19 2019-09-18 Novartis Ag Derivados de [1,2,4]-triazolo-[1,5-a]-pirimidina como inhibidores del proteasoma de protozoarios para el tratamiento de enfermedades parasitarias tales como leishmaniasis.
CA2994027C (en) 2015-07-31 2023-10-10 Merck Patent Gmbh Bicyclic heterocyclic derivatives
US10660334B2 (en) * 2016-08-15 2020-05-26 Bayer Cropscience Aktiengesellschaft Fused bicyclic heterocycle derivatives as pesticides
JP7377717B2 (ja) 2017-04-24 2023-11-10 ノバルティス アーゲー ２－アミノ－ｌ－（２－（４－フルオロフェニル）－３－（４－フルオロフェニルアミノ）－８，８－ジメチル－５，６－ジヒドロイミダゾ［１，２－ａ］ピラジン－７（８ｈ）－イル）エタノン及びそれらの組み合わせの治療レジメン
EP3652178B1 (en) 2017-07-14 2024-01-24 F. Hoffmann-La Roche AG Bicyclic ketone compounds and methods of use thereof
JP2020536853A (ja) * 2017-10-04 2020-12-17 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 転写因子ｓａｌｌ４の小分子阻害およびその使用
WO2022049548A1 (en) 2020-09-04 2022-03-10 Novartis Ag Kaf156 combinations and methods for the treatment of malaria
WO2023168107A2 (en) * 2022-03-04 2023-09-07 University Of Central Florida Research Foundation, Inc. Compounds and compositions for anitmalarial therapeutic and prophylactic use
CN114569711B (zh) * 2022-03-24 2024-04-19 安徽医科大学 一种预防弓形虫病的ME49Δcdpk3减毒活疫苗及其制备方法和应用
WO2024006971A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds
WO2024006974A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds
WO2024006970A2 (en) * 2022-07-01 2024-01-04 The Scripps Research Institute Antimalarial compounds

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK476885D0 (da) 1985-10-17 1985-10-17 Ferrosan As Heterocycliske forbindelser og fremgangsmaader til fremstilling heraf
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
DK1086086T3 (da) 1998-06-12 2005-01-24 Sod Conseils Rech Applic Imidazolylderivater og anvendelse deraf som somatostatinreceptorligander
FR2780974B1 (fr) 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
CZ20012358A3 (cs) 1998-12-31 2002-01-16 Societe De Conseils De Recherches Et D´Application Prenyltransferázové inhibitory
CZ20021550A3 (cs) 1999-11-09 2003-02-12 Societe De Conseils De Recherches Et D'application Produkt zahrnující inhibitor transdukce signálů heterotrimerického G proteinu kombinovaný s jiným protirakovinným činidlem pro terapeutické použití v léčbě rakoviny
FR2803525B1 (fr) 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
ATE360620T1 (de) 2000-08-01 2007-05-15 Sod Conseils Rech Applic Imidazolderivate
ES2241891T3 (es) * 2001-01-02 2005-11-01 F. Hoffmann-La Roche Ag Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b.
FR2825278A1 (fr) 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
WO2003082817A2 (en) 2002-03-25 2003-10-09 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1542691B1 (en) 2002-09-27 2009-01-07 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Composition for the treatment of nasopharyngeal carcinoma and use thereof
CA2508947A1 (en) * 2002-12-20 2004-07-15 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
AU2003301226A1 (en) 2002-12-20 2004-07-22 Pharmacia Corp Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2
JP2006520819A (ja) * 2003-03-06 2006-09-14 メルク　エンド　カムパニー　インコーポレーテッド 抗原虫薬イミダゾピリジン化合物
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
WO2004103276A2 (en) 2003-05-14 2004-12-02 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
FR2856688B1 (fr) 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2867778B1 (fr) * 2004-03-16 2006-06-09 Sanofi Synthelabo Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
CN101232873A (zh) 2005-08-11 2008-07-30 霍夫曼-拉罗奇有限公司 含有dpp-iv抑制剂的药物组合物
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
AU2007240364A1 (en) 2006-04-21 2007-11-01 Smithkline Beecham Corporation IL-8 receptor antagonists
US20120142623A1 (en) 2006-07-07 2012-06-07 Michael Lagunoff Compositions And Methods For Predicting Inhibitors Of Protein Targets
TW200808056A (en) * 2006-07-26 2008-02-01 Compal Communications Inc Rear projection display system
CN101622001A (zh) * 2007-01-26 2010-01-06 Irm责任有限公司 作为激酶抑制剂用于治疗疟原虫相关疾病的嘌呤化合物和组合物
US20080242862A1 (en) * 2007-03-27 2008-10-02 Calderwood David J Novel imidazo based heterocycles
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
CN101357922B (zh) 2007-08-02 2011-05-18 山东轩竹医药科技有限公司 新的dpp-iv抑制剂
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
US8338604B2 (en) 2008-06-20 2012-12-25 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
CN102471341B (zh) 2014-07-02
EP2451814B1 (en) 2014-04-09
BR112012000413B1 (pt) 2022-02-15
GT201200004A (es) 2014-03-27
US9469645B2 (en) 2016-10-18
CU20120002A7 (es) 2012-06-21
ECSP12011585A (es) 2012-02-29
HK1164304A1 (en) 2012-09-21
HN2012000023A (es) 2014-08-18
HRP20140641T1 (hr) 2014-09-26
WO2011006143A3 (en) 2011-06-09
TN2011000647A1 (en) 2013-05-24
MY157238A (en) 2016-05-13
KR101378666B1 (ko) 2014-03-26
CU24155B1 (es) 2016-03-31
CO6491060A2 (es) 2012-07-31
SI2451814T1 (sl) 2014-08-29
DK2451814T3 (da) 2014-07-14
CL2012000042A1 (es) 2012-12-21
CR20120008A (es) 2012-03-12
AU2010271247A1 (en) 2012-01-19
EP2737927A1 (en) 2014-06-04
EA201200098A1 (ru) 2012-07-30
BR112012000413A2 (pt) 2020-08-11
ES2477940T3 (es) 2014-07-18
KR20120047939A (ko) 2012-05-14
EP2451814A2 (en) 2012-05-16
SG176938A1 (en) 2012-01-30
AU2010271247B2 (en) 2013-07-18
CA2767664C (en) 2013-12-10
JP2012532890A (ja) 2012-12-20
CA2767664A1 (en) 2011-01-13
US20130281403A1 (en) 2013-10-24
US20160108051A1 (en) 2016-04-21
US8557801B2 (en) 2013-10-15
IL217384A0 (en) 2012-02-29
SMT201400096B (it) 2014-09-08
UA103930C2 (ru) 2013-12-10
TW201105675A (en) 2011-02-16
US9963454B2 (en) 2018-05-08
JP5432376B2 (ja) 2014-03-05
CN102471341A (zh) 2012-05-23
MX2012000389A (es) 2012-03-07
EP2737927B1 (en) 2016-03-30
EA019655B1 (ru) 2014-05-30
UY32776A (es) 2011-02-28
PL2451814T3 (pl) 2014-09-30
TWI421252B (zh) 2014-01-01
PE20130399A1 (es) 2013-04-06
US20110059934A1 (en) 2011-03-10
WO2011006143A2 (en) 2011-01-13
ES2574529T3 (es) 2016-06-20
IL217384A (en) 2015-07-30
NZ597275A (en) 2013-05-31
AR077463A1 (es) 2011-08-31
MA33419B1 (ar) 2012-07-03
PT2451814E (pt) 2014-07-16

Similar Documents

Publication Publication Date Title
TN2011000647A1 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases such as e.g. malaria
UA115136C2 (uk) Заміщені 4-фенілпіридини для лікування хвороб, пов'язаних з рецептором nk-1
IN2012DN00971A (ar)
IN2012DN03883A (ar)
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
WO2009152356A3 (en) Compounds and compositions useful for the treatment of malaria
IN2012DN02471A (ar)
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
MX2012004780A (es) Inhibidores de akt.
MY174883A (en) Treatment of brain cancer
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
MX2012001134A (es) Composiciones y metodos para inhibicion de la via jak.
TN2013000346A1 (en) Asymmetric ureas and medical uses thereof
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX367327B (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.
EP2528440A4 (en) SUBSTITUTED NORINDEN ISOCHINOLINE, SYNTHESIS THEREOF AND METHOD OF USE THEREOF
PH12014502065A1 (en) Vesicular formulations
WO2011014520A3 (en) Compounds and compositions as modulators of gpr119 activity
UA44410U (en) Method for treatment of hepaticocholedoch strictures
CY1115356T1 (el) Συντηγμeνες ιμιδαζολες και συνθεσεις περιλαμβανοντας αυτες για την αγωγη παρασιτικων παθησεων, οπως ειναι π.χ. η ελονοσια
TN2010000463A1 (en) Compositions and methods for preparing and using same
EP2575766A4 (en) NEW PHARMACEUTICAL COMPOUNDS
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази